Adjuvant Immunotherapy in Lung Cancer: Foundational Successes and Future Directions.

This comprehensive article explores the adjuvant use of immunotherapy in resectable lung cancer, specifically highlighting the impact of foundational trials including IMpower010 and KEYNOTE-091. These studies were the first to demonstrate improved survival with perioperative immunotherapy, particularly in programmed death-ligand 1-positive patients. The article also examines the potential of adjuvant immunotherapeutics across non-small cell lung cancer subtypes and in small cell lung cancer. Emerging therapies are discussed, emphasizing the importance of biomarker-driven approaches. Future opportunities for therapeutic development may focus on optimization of patient-specific perioperative strategies through molecular subtyping and combined therapies.

Duke Scholars

Author Kaitlin Colleen Bevers Surgery, Cardiovascular and Thoracic Surgery